Switching from compounded to brand GLP-1: when it makes sense, when it does not

TLDR. Compounded semaglutide can be 3 to 5 times cheaper than brand Wegovy. Most patients who switch from compounded to brand do so for one of four reasons: regulatory uncertainty (FDA shortage resolved October 2024), supply interruption (pharmacy shutdowns), efficacy plateau (compounded dose ceiling), or insurance approval (Wegovy now covered after PA). The switch protocol: stop compounded for one week, start brand at the dose closest to your current compounded dose (not the lowest titration step), monitor side effects. Most patients tolerate the switch without major issues.

The base case for compounded GLP-1 is simple: the active molecule is the same, the cost is a fraction and for most patients the clinical outcome is indistinguishable.

So why would anyone switch to brand? Four reasons that come up reliably in member feedback we collect. If one of them applies to you, switching makes sense. If none does, staying on compounded is the rational choice.

Reason 1: Your insurance now covers brand

This is the strongest reason. If your employer plan opens up Wegovy or Zepbound coverage during open enrollment, the math flips. Compounded at $150-$250/month versus brand at a $25-$50 copay is a roughly $1,500-$2,500/year savings for the brand path.

Open enrollment is the trigger. If you are on compounded today and your employer adds GLP-1 weight-loss coverage in January, run the prior auth process immediately. The transition is straightforward because you are already at a known dose.

Reason 2: You hit a plateau on compounded and want to try tirzepatide

Compounded semaglutide is the dominant 503A product because semaglutide is the off-patent-shortage molecule. Compounded tirzepatide exists but is harder to source legally in 2026, with most state pharmacy boards tightening enforcement. If you have been on compounded semaglutide and plateaued, the cleanest next step is brand Zepbound, not compounded tirzepatide.

The trial data supports the switch: tirzepatide's mean weight loss was 7-8 percentage points higher than semaglutide's at maximum dose. See our drug comparison for the head-to-head.

Reason 3: You are worried about a compounded shutdown

The FDA officially removed semaglutide from the drug-shortage list in February 2025. Compounding under 503A is permitted when a drug is "in shortage." When the drug exits the shortage list, the legal basis for routine 503A compounding narrows.

What this means in practice: most large compounding pharmacies have moved to a "personalized formulation" model, where the compound includes an additional active ingredient (vitamin B12, l-carnitine) that makes it not a copy of the FDA-approved drug. This is the same model used for testosterone and other classes.

The personalized-formulation route is legally defensible but the regulatory ground is moving. If you are risk-averse about supply continuity, brand is more predictable.

Reason 4: You are pregnant, trying to become pregnant or planning surgery

This is a clinical reason, not a cost reason. Brand GLP-1s are produced under FDA new-drug oversight with batch-level quality control. Compounded GLP-1s come from a 503A pharmacy under USP 797/800 standards.

USP standards are real but less stringent than FDA new-drug manufacturing. For most patients on most days, the difference is not clinically meaningful. For situations where you need maximum traceability (pregnancy planning, perioperative care, immunocompromised states), brand is the safer call.

Note that GLP-1s should be stopped before conception and held before non-emergent surgery regardless of brand vs compounded. This is not a brand-versus-compound question; it is a general GLP-1 question.

When NOT to switch

If none of the above four applies, the switch is usually a cost mistake. Specifically:

• You are losing weight at the expected rate on compounded
• You tolerate the medication without unusual side effects
• Your compounded pharmacy is one of the large established 503A operators (the named pharmacy in your program's intake documents)
• You can afford the $150-$250/month long-term

In that case, switching to brand triples your monthly cost for the same molecular result.

How to actually transition

If you have decided to switch:

1. Identify your current dose. Compounded semaglutide doses do not map exactly to brand doses, but the close approximation is: compounded 0.25 mg = brand 0.25 mg, compounded 0.5 mg = brand 0.5 mg, compounded 1.0 mg = brand 1.0 mg, compounded 1.7 mg = brand 1.7 mg, compounded 2.4 mg = brand 2.4 mg.
2. Tell your new program your current dose and ask them to continue at that level. Programs like Ro and PlushCare accept patients with established GLP-1 doses; you do not have to titrate from zero again.
3. Schedule your last compounded injection 7 days before your first brand injection. Do not double up.
4. Continue all other GLP-1 protocols (hydration, slow titration if symptoms recur, protein intake, resistance training).

Most patients transition cleanly with no breakthrough side effects, because the molecule is the same. If you do see breakthrough nausea on the first brand dose, that is likely from the slightly different excipients in the brand formulation, not the active molecule. Hold the dose for 2-3 weeks and re-titrate.

See Mochi vs Ro head-to-head for the most common compounded-to-brand transition path.

Frequently asked questions

Why would I switch from compounded to brand GLP-1?

Four common reasons. Regulatory uncertainty after the October 2024 FDA shortage resolution. Supply interruption when a compounding pharmacy gets shut down. Efficacy plateau on the compounded dose ceiling. Insurance approval that makes brand cheaper than out-of-pocket compounded. Most patients who switch cite one or two of these in combination.

What is the switch protocol from compounded to Wegovy?

Standard approach: stop compounded for 7 days, then start brand at the dose closest to your current compounded dose rather than the lowest titration step. A patient on 1 mg compounded weekly typically starts Wegovy at 1.0 mg, not 0.25 mg. The receptor is already adapted; full re-titration is unnecessary and slows progress.

Will I lose weight progress during the switch?

Usually no. A 1-week washout does not cause measurable regain in most patients. Some report a temporary appetite rebound during the gap that resolves within the first week on brand. If you are concerned about the gap, ask your prescriber whether a same-week switch (last compounded dose Monday, first brand dose the following Monday) makes sense for your situation.

Will side effects come back when I switch?

Mild GI side effects (nausea, constipation) can return briefly during the first 1 to 2 weeks on brand because of the small formulation differences. Most resolve quickly. If you are restarting at a higher dose than your compounded was, expect titration-level side effects until you adapt.

How do I know if my insurance will approve brand Wegovy?

Three questions. Does your plan's formulary list Wegovy in tier 2 or 3? Do you meet PA criteria (BMI plus comorbidity, lifestyle documentation)? Have you tried other obesity medications first (some plans require step therapy)? Most commercial plans approve 60 to 70 percent of initial PAs that meet criteria. PA can be filed before you switch off compounded so coverage is in place.